UK NHS Rolls Out New MS Drug: How Fampridine Offers Hope for Walking Mobility

UK NHS Rolls Out New MS Drug: How Fampridine Offers Hope for Walking Mobility

The NHS in England has begun routinely providing fampridine, the first licensed medicine designed specifically to improve walking in adults with multiple sclerosis, from 23 July 2026. According to NHS England, around 5,000 people with MS are expected to be eligible in the first year, marking a genuine advance in NHS neurological care. For UK patients who have long faced walking difficulties with no dedicated treatment, this NHS MS drug represents a concrete, funded route to greater mobility and independence.

This article explains what has changed, exactly how Fampridine in the UK works, who qualifies, and the practical steps MS patients and their families should take now. The central point that a basic search will not tell you is this: eligibility is tightly defined by a walking-disability score, and access depends heavily on whether your local specialist MS service has the capacity to assess you. That postcode dimension is the story behind the headlines.

What Fampridine Is and Why the NHS Rollout Matters

Fampridine, also sold under the brand name Fampyra, is a twice-daily tablet that acts as a "signal booster" for nerves damaged by MS. It is the only licensed treatment shown to improve walking ability and speed in people with the condition. Until now it was not routinely funded in England, forcing some patients to pay privately or go without.

The decision was confirmed by NHS England and reported by The BMJ on 23 July 2026 under the headline that the NHS was rolling out a "life changing" pill to help patients walk more freely. Notably, this new MS medication was not appraised through the usual NICE process. Instead, it was reviewed and approved by NHS England's Clinical Priorities Advisory Group, a route used for specialised services. That distinction matters because it means access is managed through specialist neurology and MS centres rather than routine GP prescribing.

How Fampridine works to improve walking mobility

MS damages the protective myelin coating around nerves, disrupting the electrical messages that travel from the brain to the muscles. Fampridine blocks potassium channels on the exposed nerve fibres, helping those electrical signals pass more effectively so that messages reach the leg muscles. The result, for responders, is faster and more sustained walking.

• 43% of patients saw improved walking speed in clinical trials, according to NHS England, 2026.
• Many responders were also able to walk for longer distances.
• The medicine is taken as a pill twice a day, not an injection or infusion.

Eligibility and Access for MS Patients in the UK

Eligibility for this multiple sclerosis treatment in the UK is defined by the Expanded Disability Status Scale (EDSS), a standard measure of MS disability. Patients with a score between 4 and 7 qualify. A score of 4 broadly means a person can still walk around 500 metres without an aid, while a score of 7 describes someone who cannot walk beyond about 5 metres and is largely dependent on a wheelchair.

The rollout uses a trial-then-continue model to protect NHS resources and target the drug at genuine responders:

• Patients first take fampridine for a 2 to 4 week trial.
• Their walking is formally assessed before and after the trial.
• Only those showing a clear benefit continue, with regular reviews to confirm it keeps working.

Professor James Palmer, NHS National Medical Director for Specialised Services, said: "Thousands of patients will now be able to try fampridine on the NHS, with treatment continuing where it makes a clear difference to their mobility." For readers tracking wider health articles on NHS provision, this test-and-continue approach is increasingly how the NHS introduces higher-cost specialist medicines.

Patient Testimonials and Expert Opinion

The human impact is best captured by patients who previously funded the drug themselves. Aysen Slack, 65, from Eastbourne, had paid privately for fampridine but stopped because of the cost. The NHS rollout means people in her position can now access patient care in the UK without that financial barrier.

Professor Frankie Swords, NHS National Medical Director, said: "Walking difficulties can have a huge impact on the freedom and independence of people with MS, so this signal-boosting pill could be life-changing for thousands." The charity sector welcomed the move while urging consistency. Ceri Smith, Head of Policy and Evidence at the MS Society, said: "Fampridine is the only licensed treatment that helps improve walking ability and speed for some of these people." The MS Society also pressed for MS services to be properly resourced so the drug is available nationwide regardless of where a patient lives.

The Real-World Social Impact for UK Households

Walking impairment is not an abstract clinical measure. It determines whether someone can hold down a job, climb the stairs at home, care for their children or reach the shops. The MS Society reported on 24 July 2026 that over 130,000 people in the UK are currently living with MS, and NHS England notes more than 120,000 live in England alone. For a meaningful share of them, restored walking distance is the difference between remaining in employment and claiming out-of-work support.

This has a direct bearing on disability benefits in the UK. Improved mobility can affect Personal Independence Payment (PIP) assessments, which weigh a claimant's ability to move around and complete daily tasks. Low-income households feel the loss of mobility most sharply, because they are least able to fund private treatment, home adaptations or paid care. The previous private cost of fampridine effectively created a two-tier system in which only wealthier patients could try it. Bringing it onto the NHS narrows that inequality. Carers, often family members providing unpaid support, may also see meaningful relief if a loved one regains independence. You can follow related Baba International coverage of how NHS decisions ripple through household finances and daily life.

News Analysis: Why This Happened and What It Means

The significance of this announcement lies less in the science, which has been established for years, than in the funding decision. Fampridine has been licensed and available privately in the UK for over a decade, yet it was repeatedly judged not cost-effective for routine NHS funding in England. The July 2026 approval reverses that position through the specialised commissioning route rather than a fresh NICE appraisal.

What this means in practice is a deliberate, controlled expansion. The 2 to 4 week trial and the strict EDSS 4 to 7 window are designed to concentrate spending on the roughly 5,000 patients most likely to benefit, rather than an open-ended commitment. The wider consequence is a template for how the NHS may fund other symptom-focused neurological medicines in future: fund the trial, measure the outcome, and continue only where there is proven benefit. The open question, and the one disability advocates are watching, is whether every regional MS service has the neurology capacity to deliver the required before-and-after walking assessments promptly. Without that capacity, the national policy risks becoming a local lottery.

The Future of MS Treatment in the NHS

Fampridine does not slow or cure MS; it treats a symptom. Disease-modifying therapies remain the foundation of long-term MS care, and this rollout sits alongside them as a mobility-focused addition. Even so, it signals a growing NHS willingness to fund treatments that improve day-to-day quality of life, not only those that alter disease progression. As one of the more consequential UK healthcare advancements of 2026 for neurological conditions in the UK, it may encourage further specialist commissioning of symptom therapies where the evidence supports clear, measurable benefit.

What To Do Now: Practical Steps for UK MS Patients and Families

• Contact your MS specialist or neurologist, not just your GP. Fampridine is delivered through specialist MS services, so ask your consultant or MS nurse whether you meet the EDSS 4 to 7 criteria.
• Ask specifically about a supervised 2 to 4 week trial with before-and-after walking assessment, which is the formal route to continued NHS funding.
• If you currently pay privately, do not stop your medication before speaking to your clinician about transferring to NHS supply.
• Review your benefits. If your mobility changes, check how this affects any PIP award via gov.uk, and seek advice before reporting changes.
• Contact the MS Society for support navigating access if your local service is slow to assess you.
• Register with your local MS service now if you are not already known to one, as assessment capacity may be limited in the first year.

Related Reading

• NHS Resident Doctors Strike: How Hospital Appointments and A&E Are Affected
• UK NHS AI Triage Tool: How Digital Solutions Reduce Phone Queues Today
• EU Rare Diseases Action Plan 2026: 5 Policy Shifts to Address Unmet Needs
• Digital Health Solutions: How UK NHS Accelerates AI Rollout to Cut Waiting Times Today

Frequently Asked Questions

Is Fampridine available on the NHS across all of the UK?

The confirmed rollout applies to the NHS in England from 23 July 2026, for eligible adults with MS. Provision in Scotland, Wales and Northern Ireland is decided separately by their own health bodies, so patients elsewhere in the UK should check with their local MS service.

Who qualifies for Fampridine on the NHS?

Adults with MS who have walking difficulties and an Expanded Disability Status Scale score between 4 and 7 are eligible. Patients then undergo a 2 to 4 week trial, and only those showing a clear improvement in walking continue on the medicine with regular reviews.

How effective is Fampridine at improving walking?

Clinical trials cited by NHS England in 2026 found that around 43% of patients experienced improved walking speed, and many were also able to walk for longer. It does not work for everyone, which is why the NHS uses a short trial to identify responders before committing to ongoing treatment.

Does Fampridine cure or slow MS?

No. Fampridine treats a symptom by helping nerve signals reach the muscles more effectively, improving walking for responders. It does not slow, stop or cure multiple sclerosis, and it is used alongside, not instead of, disease-modifying therapies.